Paper Details

  1. Home
  2. Paper Details

Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Author: DanesiRomano, SchmidingerManuela

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cabozantinib is approved for treating advanced renal cell carcinoma (RCC) after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. This study summarizes the safety profile of cabozantinib in RCC patients and offers guidance for managing adverse events such as diarrhea, fatigue, hypertension, hand-foot syndrome, weight loss, nausea, and stomatitis.
Paper Details　
Original Abstract of the Article :
Cabozantinib was recently approved for the treatment of advanced renal cell carcinoma (RCC) after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib is a multikinase inhibitor targeting VEGF receptor (VEGFR) 2, mesenchymal-epithelial transition receptor, and "ane...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905684/

データ提供：米国国立医学図書館（NLM）

Managing the Side Effects of Cabozantinib: A Journey Through the Desert of Cancer Treatment

The fight against cancer is a challenging journey, often marked by difficult treatments and potential side effects. This study focuses on cabozantinib, a targeted therapy used to treat advanced renal cell carcinoma (RCC). The authors, like skilled oncologists navigating the desert of cancer treatment, discuss the management of adverse events associated with cabozantinib therapy, seeking to optimize patient outcomes and minimize the impact of side effects.

Navigating the Desert of Side Effects: A Guide for Optimal Treatment

This study, like a guidebook for navigating the desert of side effects, provides valuable insights into the management of adverse events associated with cabozantinib therapy. It outlines the most common side effects, such as diarrhea, fatigue, and hand-foot syndrome, and offers practical strategies for managing these challenges. The study emphasizes the importance of proactive symptom management, early intervention, and a collaborative approach between patients and healthcare providers to ensure optimal treatment outcomes.

The Importance of Personalized Care: A Desert Oasis of Support

This study, like a well-equipped oasis in the desert of cancer treatment, highlights the importance of personalized care for patients receiving cabozantinib therapy. It underscores the need for healthcare providers to carefully monitor for side effects, tailor treatment plans to individual needs, and provide ongoing support to patients as they navigate the challenges of therapy. By fostering a patient-centered approach, we can empower individuals to manage side effects effectively and achieve optimal outcomes.

Dr. Camel's Conclusion

This study, like a caravan carrying essential supplies through the desert, underscores the importance of comprehensive care and effective symptom management for patients receiving cabozantinib therapy. By understanding the potential side effects, implementing proactive strategies, and providing personalized support, we can help patients navigate the complexities of cancer treatment with greater ease and confidence.
Date :
  1. Date Completed 2019-09-12
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

29146618

DOI: Digital Object Identifier

PMC5905684

Related Literature

Article Analysis
・Side Effects of cabozantinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.